Not a traditional drug phase: testing Antipsychotic drugs for First Episose Psychosis
The goal of this watch-and-measure (no experimental treatment required) study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis. The main question aims to measure the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose).
Official registry: https://clinicaltrials.gov/study/NCT06651112 · Université de Sherbrooke · enrollment listed as 18
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 18 people at Sherbrooke. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Impacts of Psychosis and Antipsychotics on Cerebral Energy Metabolism: the ATP Project (Antipsychotic-TEP-Psychosis)
Interventions: Antipsychotic drugs
Primary outcome (registry wording): Cerebral metabolic rate of glucose and acetotacetate
Who it is for (from inclusion criteria)
- Ages 18 Years to 35 Years
- Admission to the PEP clinic in Estrie, either outpatient or inpatient, according to the transdiagnostic PEP model
- Willingness to begin taking an AP (regardless of type and dose, or change in type and dose during the study)
- Ability to read and express themselves in French or English
- Capable of understanding and signing consent
Who the registry excludes
- Pregnancy, childbirth in the last 6 months, or breastfeeding
- Presence of a metallic object in the body that is incompatible with MRI
- Any use of APs for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription)
- The following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal
- Uncontrolled acute suicidal ideation
- Other conditions that could interfere with participation according to the judgment of the qualified physician
Public study contact (from the registry)
Melanie Fortier, M.Sc
melanie.fortier2@usherbrooke.ca
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Hotel-Dieu CIUSSS de l'Estrie-CHUS — Sherbrooke, Quebec, Canada (recruiting)
FAQ about this NCT record
Is NCT06651112 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06651112?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06651112?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary